[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Beylikduzu State Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":283},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,37,54,75,96,113,135,153,168,187,206,223,241,261],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":32,"leadSponsor":34,"locationsCount":4},"100596403","evaluation-of-balance-and-physical-performance-under-dual-task-conditions-in-individuals-with-and-without-generalized-joint-hypermobility-100596403",false,"NCT07044999","Evaluation of Balance and Physical Performance Under Dual Task Conditions in Individuals With and Without Generalized Joint Hypermobility","Inclusion Criteria:\n\n* Aged between 18 and 40 years\n* A Beighton score of 4 or higher (indicative of Generalized Joint Hypermobility)\n* Willingness to participate in the study\n\nExclusion Criteria:\n\n* Younger than 18 or older than 40 years\n* Presence of neurological disorders (e.g., stroke, multiple sclerosis, peripheral neuropathy)\n* History of vestibular system disorders (e.g., benign paroxysmal positional vertigo, vestibular neuritis)\n* History of orthopedic conditions affecting the lower extremities (e.g., fracture, joint replacement, ligament injury)\n* Cognitive impairment preventing the execution of cognitive tasks\n* Diagnosis of systemic musculoskeletal diseases (e.g., rheumatoid arthritis, Ehlers-Danlos syndrome)\n* Pregnancy\n* Participation in balance training or neurological\u002Fphysiotherapy programs within the last 6 months","ALL","18 Years","40 Years",{"count":19,"type":20},2,"ESTIMATED","1 Day","OBSERVATIONAL","This study aims to evaluate balance and physical performance under dual task conditions in individuals with and without Generalized Joint Hypermobility (GJH), as determined by the Beighton score. All participants will undergo the One-Leg Stance Test and 30-Second Sit-to-Stand Test under both single-task (balance only) and dual-task (simultaneous cognitive task) conditions. The cognitive task will involve counting backward by sevens from a given number. Participants will also complete the Timed Up and Go (TUG) test under both single- and dual-task conditions. Additionally, the Berg Balance Scale (BBS) will be used for comprehensive balance assessment. Balance confidence will be evaluated using the Activities-specific Balance Confidence Scale (ABC-16), and fear of falling will be assessed with the Falls Efficacy Scale-International (FES-I). Changes in performance under dual-task conditions will be expressed as a percentage using the Dual Task Cost (DTC) formula",[25],"Hypermobility Syndrome","NOT_YET_RECRUITING","2025-06-22",{"date":29,"type":30},"2025-07-01","ACTUAL",{"date":29,"type":20},{"date":33,"type":20},"2025-08-01",{"name":35,"class":36},"Beylikduzu State Hospital","OTHER",{"id":38,"slug":39,"hasResults":11,"nctId":40,"briefTitle":41,"officialTitle":41,"acronym":4,"eligibilityCriteria":42,"healthyVolunteers":43,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":44,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":46,"conditions":47,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":49,"startDateStruct":50,"completionDateStruct":51,"leadSponsor":52,"locationsCount":53},"100596402","ultrasonographic-evaluation-of-the-ulnar-nerve-in-individuals-with-and-without-generalized-joint-hypermobility-100596402","NCT07044986","Ultrasonographic Evaluation of the Ulnar Nerve in Individuals With and Without Generalized Joint Hypermobility","Inclusion Criteria:\n\n* Aged between 18 and 40 years\n* A Beighton score of 4 or higher (indicative of Generalized Joint Hypermobility)\n* Willingness to participate in the study\n\nExclusion Criteria:\n\n* Being under 18 or over 40 years of age\n* History of surgery or fracture in the elbow region\n* Presence of active infection at the measurement site\n* Presence of congenital anomaly in the upper extremity\n* History of surgery involving neural structures in the upper extremity\n* Presence of malignancy\n* Pregnancy\n* Presence of cognitive or psychiatric disorders",true,{"count":45,"type":20},60,"This study will include 30 individuals diagnosed with Generalized Joint Hypermobility (GJH) based on the Beighton score and 30 healthy controls without GJH. Participants will undergo Tinel's test and the flexion-compression test. The presence of ulnar nerve-related symptoms such as pain and numbness will be recorded. Ultrasonographic evaluation of the ulnar nerve will be performed at the level of the medial epicondyle, as well as 2 cm proximal and distal to it. Cross-sectional area and diameter of the ulnar nerve will be measured at each site, repeated three times, and the average will be used. Additionally, ulnar nerve mobility during elbow flexion and extension will be assessed. The nerve will be classified as stable if it remains within the cubital tunnel, subluxated if it moves to the level of the epicondyle, and dislocated if it shifts anterior to the medial epicondyle.",[48],"Hypermobility, Joint",{"date":29,"type":30},{"date":29,"type":20},{"date":33,"type":20},{"name":35,"class":36},1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":66,"conditions":67,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":69,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":4},"100596404","the-relationship-between-osteoporosis-and-sarcopenia-parameters-in-postmenopausal-women-under-60-100596404","NCT07045012","The Relationship Between Osteoporosis and Sarcopenia Parameters in Postmenopausal Women Under 60","The Relationship Between Osteoporosis and Sarcopenia Parameters in Postmenopausal Women Under 60: A Cross-Sectional Study","Inclusion Criteria:\n\n* Women under 60 years of age who are postmenopausal.\n* Patients with or without a diagnosis of osteoporosis:\n\nOsteoporosis group: T-score ≤ -2.5 in femoral neck or L1-L4 region. Control group: T-score ≥ -1.0 in femoral neck and L1-L4 region.\n\n-Patients who provide written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Refusal to participate in the study.\n* Presence of neuromuscular diseases that could cause muscle loss.\n* History of infection, recent surgery, or trauma.\n* Presence of psychiatric disorders.\n* Cognitive impairment that could interfere with test performance or data reliability.\n* Use of medications that could affect study outcomes (e.g., corticosteroids, muscle relaxants, or medications influencing bone\u002Fmuscle metabolism).","FEMALE","50 Years","59 Years",{"count":65,"type":20},52,"This cross-sectional study will include postmenopausal women under the age of 60 who visited the Physical Medicine and Rehabilitation outpatient clinic at Beylikdüzü State Hospital between June 25 and July 25, 2025. Participants must have undergone a bone mineral density (BMD) assessment within the past six months using Dual X-ray Absorptiometry (DXA). Both osteoporotic and non-osteoporotic patients will be enrolled. Sociodemographic data such as age, height, weight, and BMI will be recorded. Femoral neck and L1-L4 T-scores and BMD values will be obtained from existing DXA results. Information on osteoporosis treatment, presence of fecal incontinence, constipation, and medication use will be collected. In the second phase, sarcopenia will be assessed according to EWGSOP2 criteria using bioelectrical impedance analysis for skeletal muscle mass, handgrip strength, and the five-time sit-to-stand test. Differences between the osteoporotic and non-osteoporotic groups will be analyzed.",[68],"Osteoporosis",{"date":29,"type":30},{"date":71,"type":20},"2025-06-25",{"date":73,"type":20},"2025-07-25",{"name":35,"class":36},{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":61,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":93,"leadSponsor":95,"locationsCount":53},"100588884","orthorexia-nervosa-in-postmenopausal-osteoporosis-100588884","NCT06947213","Orthorexia Nervosa in Postmenopausal Osteoporosis","Fragile Bones, Strong Obsessions: A Controlled Study on Orthorexia Nervosa, Body Image and Mood in Postmenopausal Women With Osteoporosis","Inclusion Criteria:\n\n* Women between 55-75 years\n* Women diagnosed with osteoporosis based on DXA measurements performed within the past six months.\n* Women aged similarly to the osteoporosis group without a diagnosis of osteoporosis (healthy controls).\n* Willingness to participate and provision of written informed consent.\n\nExclusion Criteria:\n\n* Refusal to participate in the study.\n* Diagnosed psychiatric disorders.\n* Cognitive impairment.\n* Presence of malignancy.\n* Presence of endocrine disorders (e.g., hyperthyroidism, Cushing's syndrome).\n* Use of glucocorticoids.\n* Use of medications affecting mood.","55 Years","75 Years",{"count":85,"type":20},128,"A total of 64 female patients diagnosed with osteoporosis based on dual-energy X-ray absorptiometry (DXA) measurements performed within the last six months, and 64 age-matched healthy controls without osteoporosis, will be included in our study. Sociodemographic data such as age, sex, height, weight, and BMI will be recorded. Additionally, information regarding the duration of osteoporosis diagnosis, current treatments, history of fractures, history of falls, comorbidities, and smoking status will be collected. Femoral neck and L1-L4 T-scores and bone mineral density values obtained from existing DXA scans will be documented. Orthorexia nervosa-related symptoms will be assessed using the ORTO-11 scale, mood will be evaluated using the Hospital Anxiety and Depression Scale (HADS), and body image will be assessed using the Body Appreciation Scale-2.",[68],"RECRUITING","2025-04-20",{"date":91,"type":30},"2025-04-27",{"date":89,"type":30},{"date":94,"type":20},"2025-05-20",{"name":35,"class":36},{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":61,"minAge":16,"maxAge":103,"enrollmentInfo":104,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":109,"startDateStruct":110,"completionDateStruct":111,"leadSponsor":112,"locationsCount":53},"100588883","orthorexia-nervosa-in-fibromyalgia-100588883","NCT06947200","Orthorexia Nervosa in Fibromyalgia","Is There a Link Between Orthorexia Nervosa, Body Image and Psychological State in Women With Fibromyalgia Syndrome?","Inclusion Criteria:\n\n* Female patients aged 18-65 years.\n* Diagnosis of fibromyalgia syndrome according to the 2010 American College of Rheumatology diagnostic criteria.\n* Willingness to participate and provision of written informed consent.\n\nExclusion Criteria:\n\n* Refusal to participate.\n* Presence of diagnosed psychiatric disorders.\n* Presence of cognitive impairment.\n* Use of medications that may affect mood.","65 Years",{"count":105,"type":20},84,"This clinical cross-sectional study will include 84 female patients aged between 18 and 65 years who have been diagnosed with fibromyalgia syndrome according to the 2010 American College of Rheumatology diagnostic criteria. Sociodemographic data will be recorded at the beginning of the study. Pain severity will be assessed using the Visual Analog Scale (VAS). Orthorexia nervosa-related symptoms will be evaluated with the ORTO-11 scale. Body image will be assessed with the Body Appreciation Scale 2, mood will be evaluated using the Hospital Anxiety and Depression Scale (HADS), and fibromyalgia-related impact will be assessed with the Fibromyalgia Impact Questionnaire (FIQ).",[108],"Fibromyalgia",{"date":91,"type":30},{"date":89,"type":30},{"date":94,"type":20},{"name":35,"class":36},{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":15,"minAge":120,"maxAge":121,"enrollmentInfo":122,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":53},"100583299","second-toe-length-and-hallux-valgus-greek-vs-egyptian-foot-100583299","NCT06874517","Second Toe Length and Hallux Valgus: Greek vs. Egyptian Foot","Greek vs. Egyptian Foot: The Impact of Second Toe Length on Hallux Valgus Development","Inclusion Criteria:\n\n* Age between 60-80 years\n* Presence of foot radiographs suitable for measurement\n* No history of prior foot surgery\n\nExclusion Criteria:\n\n* History of foot trauma or fractures\n* Previous foot or toe surgery\n* Presence of congenital foot deformities\n* Neurological or rheumatologic conditions affecting foot structure\n* Severe osteoarthritis or other degenerative foot diseases visible on radiographs","60 Years","80 Years",{"count":123,"type":20},150,"A total of 150 patients aged 60-80 years with existing foot radiographs will be included in the study. Radiographic evaluations will include measurements of the hallux valgus angle, first intermetatarsal angle, and the metatarsal and phalanx lengths of the first and second toes. The ratio of the second toe phalanx length to the first toe phalanx length will be calculated and recorded. The relationship between the hallux valgus angle, toe lengths, and their ratios will be analyzed using statistical methods.",[126],"Hallux Valgus","2025-03-22",{"date":129,"type":30},"2025-03-26",{"date":131,"type":30},"2025-03-10",{"date":133,"type":20},"2025-04-10",{"name":35,"class":36},{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":15,"minAge":17,"maxAge":121,"enrollmentInfo":142,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":144,"conditions":145,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":152,"locationsCount":53},"100584697","caregiver-burden-in-parkinsons-disease-100584697","NCT06892717","Caregiver Burden in Parkinson's Disease","Caregiver Burden and Associated Factors in Parkinson's Disease","Inclusion Criteria:\n\n* Age between 40-80 years\n* Diagnosed with Parkinson's disease, Hoehn and Yahr stage 2-5\n* Requires assistance in daily activities\n* Informal caregiver providing care (unpaid, typically a family member such as a spouse or child)\n* Caregiver has sufficient proficiency in Turkish to understand and respond to the study questions\n\nExclusion Criteria:\n\n* Presence of any additional neurodegenerative disease other than Parkinson's disease\n* Diagnosis of Chronic Obstructive Pulmonary Disease (COPD)\n* Advanced heart failure classified as New York Heart Association (NYHA) Class IV (symptoms at rest)\n* Active cancer disease\n* History of stroke causing limitations in daily life\n* Immobility due to reasons other than Parkinson's disease",{"count":143,"type":20},43,"Primary caregivers of patients diagnosed with idiopathic Parkinson's disease will be included in the study. A total of 43 participants will be recruited. At the beginning of the study, demographic data and clinical characteristics of the patients, including disease stage, history of falls, presence of fractures, presence and severity of pain, comorbidities, and medication use, will be recorded.\n\nSubsequently, caregivers' age, gender, occupation, relationship to the patient, caregiving duration, and their own comorbidities will be assessed. Sleep problems will be evaluated using the Insomnia Severity Index (ISI), while symptoms related to depression and anxiety will be assessed with the Hospital Anxiety and Depression Scale (HADS). Caregiver burden will be examined using the Zarit Caregiver Burden Scale.",[146],"Parkinson Disease",{"date":148,"type":30},"2025-03-25",{"date":150,"type":30},"2025-02-10",{"date":133,"type":20},{"name":35,"class":36},{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":103,"enrollmentInfo":160,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":161,"conditions":162,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":164,"startDateStruct":165,"completionDateStruct":166,"leadSponsor":167,"locationsCount":53},"100583322","masseter-thickness-bruxism-and-oral-behaviors-in-chronic-neck-pain-100583322","NCT06874816","Masseter Thickness, Bruxism, and Oral Behaviors in Chronic Neck Pain","Does Your Jaw Tell the Story of Your Pain? Masseter Muscle Thickness, Bruxism, and Oral Behaviors in Chronic Non-Specific Neck Pain","Inclusion Criteria:\n\n* Diagnosed with chronic non-specific neck pain\n* Aged between 18-65 years\n* Symptoms persisting for at least 3 months\n\nExclusion Criteria:\n\n* Pregnancy\n* Presence of psychiatric or neurological diseases\n* Use of psychiatric medications\n* Cognitive impairment\n* History of neck injection or surgery within the last 6 months\n* Presence of rheumatic diseases\n* Spinal stenosis\n* Cervical disc herniation\n* Advanced degeneration detected in radiological imaging\n* History of fracture or surgery in the temporomandibular joint\n* Presence of inflammatory, rheumatologic diseases, or malignancy affecting the t--emporomandibular joint",{"count":45,"type":20},"A total of 30 patients aged 18-65 years who present with chronic non-specific neck pain and 30 healthy volunteers will be included in the study. Patients with symptoms persisting for at least 3 months will be eligible for inclusion. Necessary information will be provided to all participants, and informed consent will be obtained.\n\nTo assess pain severity before treatment, participants will be asked to rate their complaints using the Visual Analog Scale (VAS), a linear scale for pain assessment. The Neck Disability Index will be used to determine the level of disability.\n\nThe Jaw Functional Limitation Scale-20 (JFLS-20), Patient Health Questionnaire-9 (PHQ-9), Patient Health Questionnaire-15: Physical Symptoms, Generalized Anxiety Disorder-7 (GAD-7), and the Oral Behaviors Checklist-included in Axis 2 of the DC\u002FTMD form developed for evaluating temporomandibular joint dysfunction-will be used to assess patients' psychosocial characteristics and parafunctional habits.\n\nAdditionally, masseter muscle thickness will be evaluated using ultrasonographic measurement.",[163],"Neck Pain",{"date":129,"type":30},{"date":131,"type":30},{"date":133,"type":20},{"name":35,"class":36},{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":15,"minAge":62,"maxAge":121,"enrollmentInfo":175,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":177,"conditions":178,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":53},"100573862","balance-confidence-and-kinesiophobia-in-parkinsons-disease-100573862","NCT06751797","Balance Confidence and Kinesiophobia in Parkinson's Disease","Balance Confidence, Kinesiophobia, and Associated Factors in Parkinson's Disease: A Controlled Study","Inclusion Criteria:\n\n* Diagnosis of Idiopathic Parkinson's Disease by a neurology specialist.\n* Modified Hoehn-Yahr Staging Scale classification between stages 1-3.\n* Mini-Mental State Examination (MMSE) score of 24 or higher.\n* Age between 50-80 years.\n* Volunteered to participate in the study.\n\nExclusion Criteria:\n\n* Use of medications, apart from routine Parkinson's disease treatments, that could affect balance or muscle strength.\n* Presence of neurological or musculoskeletal conditions other than Parkinson's disease.\n* Refusal to participate in the study.\n* Presence of psychiatric disorders.\n* Presence of cognitive impairments.",{"count":176,"type":20},62,"31 patients aged 50-80 years diagnosed with idiopathic Parkinson's disease (Modified Hoehn-Yahr stages 1-3) and 31 healthy volunteers. At the start of the study, sociodemographic data for all participants will be recorded. To assess the mental and functional status of Parkinson's disease patients, the Mini-Mental State Examination (MMSE) and the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) will be used. Balance confidence levels will be assessed using the Activities-specific Balance Confidence Scale-6 (ABC-6), overall balance using the Berg Balance Scale (BBS), fear of falling using the Falls Efficacy Scale (FES), and kinesiophobia levels using the Tampa Scale of Kinesiophobia (TSK).",[146],"2024-12-26",{"date":181,"type":30},"2024-12-30",{"date":183,"type":30},"2024-12-10",{"date":185,"type":20},"2025-01-20",{"name":35,"class":36},{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":83,"enrollmentInfo":194,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":196,"conditions":197,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":203,"leadSponsor":205,"locationsCount":53},"100572242","thenar-muscle-ultrasound-in-cts-evaluation-100572242","NCT06730724","Thenar Muscle Ultrasound in CTS Evaluation","Is Ultrasound Measurement of Thenar Muscle Cross-Sectional Area Useful in the Evaluation of Carpal Tunnel Syndrome?: A Controlled Study","Inclusion Criteria:\n\n* Patients aged 18-75 years.\n* Diagnosed with carpal tunnel syndrome based on electrophysiological examination within the last 3 months.\n* Healthy volunteers without a diagnosis of carpal tunnel syndrome.\n* Volunteered to participate in the study.\n\nExclusion Criteria:\n\n* Refusal to participate in the study.\n* History of surgery due to carpal tunnel syndrome.\n* Presence of neuromuscular diseases.\n* Presence of advanced osteoarthritis.\n* Presence of psychiatric disorders.\n* Presence of cognitive impairments that may hinder study participation.",{"count":195,"type":20},40,"This study will include 20 patients aged 18-75 years who have been diagnosed with carpal tunnel syndrome (CTS) based on electrophysiological examinations performed within the last three months, as well as 20 healthy volunteers without a CTS diagnosis. Sociodemographic data such as age, gender, height, weight, and BMI will be recorded. Pinch grip strength will be evaluated using a Jamar pinch meter, and hand grip strength will be assessed using a Jamar dynamometer. Ultrasound will be used to measure the cross-sectional area and thickness of the thenar muscles as well as the cross-sectional area of the median nerve. Additionally, previous electrophysiological examination results will be recorded for the CTS patients.",[198],"Carpal Tunnel Syndrome","2024-12-09",{"date":201,"type":30},"2024-12-12",{"date":183,"type":20},{"date":204,"type":20},"2025-01-10",{"name":35,"class":36},{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":103,"enrollmentInfo":212,"targetDuration":214,"studyType":22,"phases":4,"briefSummary":215,"conditions":216,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":217,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":53},"100566723","comparison-of-the-efficacy-of-ultrasound-guided-corticosteroid-injection-and-paraffin-therapy-in-carpal-tunnel-syndrome-100566723","NCT06658886","Comparison of the Efficacy of Ultrasound-Guided Corticosteroid Injection and Paraffin Therapy in Carpal Tunnel Syndrome","Inclusion Criteria:\n\n* Patients aged 18-65.\n* Diagnosed with mild to moderate carpal tunnel syndrome based on electrophysiological studies.\n* Received either ultrasound-guided corticosteroid injection or paraffin therapy.\n* Symptoms persisting for at least 3 months.\n\nExclusion Criteria:\n\n* Diagnosis of other conditions causing neuropathic symptoms (e.g., polyneuropathy, brachial plexopathy, thoracic outlet syndrome).\n* History of previous injection or surgery for carpal tunnel syndrome.",{"count":213,"type":20},46,"3 Months","The aim of this study is to compare the efficacy of paraffin therapy, a physical therapy modality, and ultrasound-guided corticosteroid injection in the treatment of carpal tunnel syndrome, the most common entrapment neuropathy. By doing so, the study will evaluate the effectiveness and feasibility of these two alternative, low-side-effect treatments for managing this frequently encountered condition.",[198],{"date":201,"type":30},{"date":219,"type":30},"2024-11-10",{"date":221,"type":20},"2025-02-25",{"name":35,"class":36},{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":43,"sex":61,"minAge":62,"maxAge":83,"enrollmentInfo":230,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":232,"conditions":233,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":235,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":53},"100566478","stress-urinary-incontinence-and-sarcopenia-in-postmenopausal-osteoporosis-100566478","NCT06655701","Stress Urinary Incontinence and Sarcopenia in Postmenopausal Osteoporosis","Stress Urinary Incontinence and Sarcopenia in Postmenopausal Osteoporosis: The Intersection of Muscle Loss and Pelvic Dysfunction","Inclusion Criteria:\n\n* Postmenopausal women with DXA measurements performed within the last 6 months.\n* Based on DXA measurements:\n\nFemoral neck and L1-L4 T-scores of -1 and above will be included in the control group (non-osteoporotic).\n\nFemoral neck and L1-L4 T-scores of -2.5 and below will be included in the osteoporosis group.\n\n* Aged 50-75 years\n\nExclusion Criteria:\n\n* Refusal to participate in the study.\n* History of neurological diseases, infections, surgeries, or trauma that could cause urinary incontinence or muscle loss.\n* Presence of psychiatric disorders.\n* Cognitive impairments.\n* Use of medications that could affect the study results.",{"count":231,"type":20},100,"The primary aim of our study is to evaluate the presence of stress urinary incontinence in postmenopausal patients with and without osteoporosis, determine its impact on quality of life, and explore its relationship with sarcopenia.",[234],"Osteoporosis, Postmenopausal",{"date":201,"type":30},{"date":237,"type":30},"2024-11-15",{"date":239,"type":20},"2025-01-15",{"name":35,"class":36},{"id":242,"slug":243,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":4,"eligibilityCriteria":247,"healthyVolunteers":43,"sex":15,"minAge":248,"maxAge":249,"enrollmentInfo":250,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":251,"conditions":252,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":258,"leadSponsor":260,"locationsCount":53},"100568280","fall-frequency-in-children-with-cerebral-palsy-100568280","NCT06679166","Fall Frequency in Children With Cerebral Palsy","Evaluation of Fall Frequency in Children With Cerebral Palsy: A Controlled Study","Inclusion Criteria:\n\n* Children aged 5-12 years.\n* Diagnosed with cerebral palsy (study group) or healthy without cerebral palsy (control group).\n* Ability to ambulate either independently or with assistance indoors or in the community.\n* Consent obtained from the participant or their caregiver (parent or guardian).\n\nExclusion Criteria:\n\n* Refusal to participate in the study.\n* Presence of cognitive impairments.\n* Existence of neuromuscular diseases, other than cerebral palsy, that would impair walking ability or increase fall frequency.","5 Years","12 Years",{"count":213,"type":20},"The aim of this cross-sectional clinical study is to evaluate the frequency of falls in children diagnosed with cerebral palsy and compare it with healthy controls.",[253],"Cerebral Palsy","2024-11-06",{"date":256,"type":30},"2024-11-07",{"date":219,"type":20},{"date":259,"type":20},"2024-12-20",{"name":35,"class":36},{"id":262,"slug":263,"hasResults":11,"nctId":264,"briefTitle":265,"officialTitle":265,"acronym":4,"eligibilityCriteria":266,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":103,"enrollmentInfo":267,"targetDuration":214,"studyType":22,"phases":4,"briefSummary":268,"conditions":269,"keywords":270,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":282,"locationsCount":53},"100547243","comparison-of-the-efficacy-of-peloid-therapy-and-paraffin-treatment-in-carpal-tunnel-syndrome-100547243","NCT06405438","Comparison of the Efficacy of Peloid Therapy and Paraffin Treatment in Carpal Tunnel Syndrome","Inclusion Criteria:\n\n* Patients aged between 18 and 65 years old.\n* Patients diagnosed with mild to moderate carpal tunnel syndrome based on electrophysiological evaluations.\n* Patients experiencing symptoms for a minimum of 3 months.\n\nExclusion Criteria:\n\n* Patients diagnosed with neuropathic conditions such as polyneuropathy, brachial plexopathy, or thoracic outlet syndrome.\n* Patients with a history of previous injections or surgery for carpal tunnel syndrome.",{"count":45,"type":20},"This study compares the effectiveness of peloid therapy and paraffin treatment in carpal tunnel syndrome. Patients who have already received 2 weeks of peloid therapy or 15 sessions of paraffin treatment will be assessed. Pain and symptom severity are assessed using the Visual Analog Scale (VAS) and Boston Carpal Tunnel Syndrome Questionnaire (BCTQ). Electrophysiological examinations will also be conducted at the same time points: baseline, 4 weeks post-treatment, and a 12-week follow-up.",[198],[271,272,273,274,275],"carpal tunnel syndrome","median neuropathy","median nerve","peloid therapy","mud therapy","2024-10-23",{"date":278,"type":30},"2024-10-26",{"date":280,"type":30},"2024-10-10",{"date":185,"type":20},{"name":35,"class":36},""]